By: Dividend Sensei
All pharmaceuticals have been hit in recent months by concerns over healthcare reform. However, Teva Pharmaceuticals in particular has experienced a rash of bad news that has absolutely crushed the stock and sent its yield soaring to among the highest in the industry. Find out why investors shouldn’t be worried about the safety of the payout, and why this represents an excellent long-term buying opportunity for patient investors.
I’m an Army veteran and former energy dividend writer for The Motley Fool. I currently write for both Seeking Alpha, Simply Safe Dividends, Investorplace.com, and TheStreet.com.
My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams, and enrich their lives. With 20 years of investing experience, I’ve learned what works and more importantly, what doesn’t, when it comes to building long-term wealth and income streams. I’m currently on an epic quest to build a broadly diversified, high-quality, high-yield dividend growth portfolio that:
1. Pays a 4% to 5% yield
2. Offers 9% to 10% annual dividend growth
3. Pays dividends AT LEAST on a weekly, but preferably, daily basis
September 15, 2017